Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF

Trial Profile

Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms PARASAIL
  • Sponsors Novartis
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 30 Dec 2017 to 15 Nov 2017.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 14 May 2017.
    • 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top